Form 4: REGENXBIO CMO's Routine Tax-Related Stock Sale

REGENXBIO's Chief Medical Officer, Steve Pakola, disposed of 5,267 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Steve Pakola, Chief Medical Officer of REGENXBIO Inc. (RGNX), reported a disposition of 5,267 shares of common stock.
• The transaction occurred on February 1, 2026, with the shares valued at $11.16 each.
• These shares were withheld to satisfy tax obligations upon the vesting of restricted stock units (RSUs).
• The restricted stock units were originally granted to Mr. Pakola on August 1, 2024.
• Following this transaction, Mr. Pakola's direct beneficial ownership stands at 253,050 shares of REGENXBIO common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes related to executive compensation and does not reflect a change in company fundamentals or management's discretionary sentiment towards the stock.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing tax-related dispositions upon RSU vesting are routine and common for executives of publicly traded companies. These transactions are typically non-discretionary and are a standard part of executive compensation plans, reflecting the settlement of tax liabilities rather than a discretionary sale based on an executive's view of the company's prospects. This particular filing for REGENXBIO's CMO is consistent with such routine disclosures across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations upon RSU vesting. Such a transaction does not provide new information about the company's operational performance, strategic direction, or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and evaluate REGENXBIO based on its core business fundamentals, clinical pipeline, and financial results.

Keywords

REGENXBIO, RGNX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Chief Medical Officer, Steve Pakola